Följ
Panagiota Zygoura
Panagiota Zygoura
Statistician in Frontier Science Foundation - Hellas
Verifierad e-postadress på frontier-science.gr - Startsida
Titel
Citeras av
Citeras av
År
Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score
NI Cherny, EGE De Vries, U Dafni, E Garrett-Mayer, SE McKernin, ...
Journal of Clinical Oncology 37 (4), 336-349, 2019
1082019
Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project
I Letovanec, S Finn, P Zygoura, P Smyth, A Soltermann, L Bubendorf, ...
Journal of Thoracic Oncology 13 (3), 413-425, 2018
752018
Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
S Banerjee, U Dafni, T Allen, D Arnold, G Curigliano, E Garralda, ...
ESMO open 3 (6), e000422, 2018
702018
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M …
RA Soo, JY Han, U Dafni, BC Cho, CM Yeo, E Nadal, E Carcereny, ...
Annals of Oncology 33 (2), 181-192, 2022
562022
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy–results from the randomised phase II ETOP/IFCT 4-12 …
S Peters, JL Pujol, U Dafni, M Dómine, S Popat, M Reck, J Andrade, ...
Annals of Oncology 33 (1), 67-79, 2022
502022
Report on the status of women occupying leadership roles in oncology
E Hofstädter-Thalmann, U Dafni, T Allen, D Arnold, S Banerjee, ...
ESMO open 3 (6), e000423, 2018
442018
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
B Gyawali, EGE De Vries, U Dafni, T Amaral, J Barriuso, J Bogaerts, ...
ESMO open 6 (3), 100117, 2021
422021
Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients
K Homicsko, G Richtig, F Tuchmann, Z Tsourti, D Hanahan, G Coukos, ...
Annals of Oncology 29, x40, 2018
372018
EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1. 1) for haematological malignancies
B Kiesewetter, NI Cherny, N Boissel, F Cerisoli, U Dafni, EGE De Vries, ...
ESMO open 5 (1), e000611, 2020
142020
Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines
G Zarkavelis, AL Amylidi, C Verbaanderd, NI Cherny, Y Metaxas, ...
ESMO open 8 (1), 100604, 2023
82023
Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V. 1.1
DG Knapen, NI Cherny, P Zygoura, NJ Latino, JY Douillard, U Dafni, ...
ESMO open 5 (5), e000681, 2020
82020
Computer-based intensity measurement assists pathologists in scoring phosphatase and tensin homolog immunohistochemistry—clinical associations in NSCLC patients of the …
U Rulle, Z Tsourti, R Casanova, KF Deml, E Verbeken, E Thunnissen, ...
Journal of Thoracic Oncology 13 (12), 1851-1863, 2018
82018
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS: H) version 1.0
B Kiesewetter, U Dafni, EGE de Vries, J Barriuso, G Curigliano, ...
Annals of Oncology 34 (9), 734-771, 2023
52023
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
U Dafni, RA Soo, S Peters, Z Tsourti, P Zygoura, K Vervita, JY Han, ...
ESMO open 7 (3), 100507, 2022
52022
Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period
C Lazor-Blanchet, P Zygoura, U Dafni, F Lamoth, Z Tsourti, MA Lobritz, ...
The Journal of Infection 84 (5), 722, 2022
42022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial
GL Banna, A Addeo, P Zygoura, Z Tsourti, S Popat, A Curioni-Fontecedro, ...
Lung Cancer 169, 77-83, 2022
12022
European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European …
I Opitz, A Bille, U Dafni, K Nackaerts, L Ampollini, M de Perrot, L Brcic, ...
Journal of Thoracic Oncology 18 (9), 1233-1247, 2023
2023
PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS: H) VERSION 1.0
B Kiesewetter, U Dafni, EGE De Vries, J Barriuso, G Curigliano, ...
HemaSphere 7 (S3), e02308e3, 2023
2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
K Homicsko, P Zygoura, M Norkin, S Tissot, N Shakarishvili, S Popat, ...
Journal for Immunotherapy of Cancer 11 (10), 2023
2023
11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma
K Homicsko, P Zygoura, S Tissot, M Norkin, S Popat, ...
Immuno-Oncology and Technology 16, 2022
2022
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20